Ausgabe 3/2013
Inhalt (21 Artikel)
Contralateral prophylactic mastectomy and survival: report from the National Cancer Data Base, 1998–2002
Katharine Yao, David J. Winchester, Tomasz Czechura, Dezheng Huo
DNA from dead cancer cells induces TLR9-mediated invasion and inflammation in living cancer cells
Johanna Tuomela, Jouko Sandholm, Mika Kaakinen, Ankita Patel, Joonas H. Kauppila, Joanna Ilvesaro, Dongquan Chen, Kevin W. Harris, David Graves, Katri S. Selander
Role of HGF in obesity-associated tumorigenesis: C3(1)-TAg mice as a model for human basal-like breast cancer
Sneha Sundaram, Alex J. Freemerman, Amy R. Johnson, J. Justin Milner, Kirk K. McNaughton, Joseph A. Galanko, Katharine M. Bendt, David B. Darr, Charles M. Perou, Melissa A. Troester, Liza Makowski
A relative ordering-based predictor for tamoxifen-treated estrogen receptor-positive breast cancer patients: multi-laboratory cohort validation
Xianxiao Zhou, Bailiang Li, Yuannv Zhang, Yunyan Gu, Beibei Chen, Tongwei Shi, Lu Ao, Pengfei Li, Shan Li, Chunyang Liu, Zheng Guo
Single-strand selective monofunctional uracil-DNA glycosylase (SMUG1) deficiency is linked to aggressive breast cancer and predicts response to adjuvant therapy
Tarek M. A. Abdel-Fatah, Nada Albarakati, Lara Bowell, Devika Agarwal, Paul Moseley, Claire Hawkes, Graham Ball, Stephen Chan, Ian O. Ellis, Srinivasan Madhusudan
Long non-coding RNA HOTAIR is an independent prognostic marker of metastasis in estrogen receptor-positive primary breast cancer
Kristina P. Sørensen, Mads Thomassen, Qihua Tan, Martin Bak, Søren Cold, Mark Burton, Martin J. Larsen, Torben A. Kruse
Tamoxifen selects for breast cancer cells with mammosphere forming capacity and increased growth rate
Diego Raffo, Damian E. Berardi, Osvaldo Pontiggia, Laura Todaro, Elisa Bal de Kier Joffé, Marina Simian
Superior outcome after neoadjuvant chemotherapy with docetaxel, anthracycline, and cyclophosphamide versus docetaxel plus cyclophosphamide: results from the NATT trial in triple negative or HER2 positive breast cancer
Xiaosong Chen, Guolin Ye, Chenfang Zhang, Xinzheng Li, Yiding Chen, Xiaohong Xie, Hong Zheng, Yali Cao, Kejin Wu, Duo Ni, Jinhai Tang, Ziguo Wei, Kunwei Shen
Adjuvant tamoxifen-induced mammographic breast density reduction as a predictor for recurrence in estrogen receptor-positive premenopausal breast cancer patients
Kyung Lan Ko, In Suk Shin, Ji Young You, So-Youn Jung, Jungsil Ro, Eun Sook Lee
Circulating hormones and breast cancer risk in premenopausal women: a randomized trial of low-dose tamoxifen and fenretinide
Harriet Johansson, Bernardo Bonanni, Sara Gandini, Aliana Guerrieri-Gonzaga, Massimiliano Cazzaniga, Davide Serrano, Debora Macis, Antonella Puccio, Maria Teresa Sandri, Marcella Gulisano, Franca Formelli, Andrea DeCensi
Comparing the outcome between multicentric and multifocal breast cancer: what is the impact on survival, and is there a role for guideline-adherent adjuvant therapy? A retrospective multicenter cohort study of 8,935 patients
R. Wolters, A. Wöckel, W. Janni, I. Novopashenny, F. Ebner, R. Kreienberg, M. Wischnewsky, L. Schwentner
Radiotherapy in implant-based immediate breast reconstruction: risk factors, surgical outcomes, and patient-reported outcome measures in a large Swedish multicenter cohort
Max Eriksson, Lotta Anveden, Fuat Celebioglu, Kristina Dahlberg, Ingrid Meldahl, Jakob Lagergren, Catharina Eriksen, Jana de Boniface
Use of the metastatic breast cancer progression (MBC-P) questionnaire to assess the value of progression-free survival for women with metastatic breast cancer
Sara A. Hurvitz, Deepa Lalla, Ross D. Crosby, Susan D. Mathias
Risk-reducing surgery increases survival in BRCA1/2 mutation carriers unaffected at time of family referral
Sarah L. Ingham, Matthew Sperrin, Andrew Baildam, Gary L. Ross, Richard Clayton, Fiona Lalloo, Iain Buchan, Anthony Howell, D. Gareth R. Evans
Promoter methylation of BRCA1 in the prognosis of breast cancer: a meta-analysis
Liang Wu, Fengliang Wang, Ruobing Xu, Simin Zhang, Xianzhen Peng, Yan Feng, Jianming Wang, Cheng Lu
Age related risk of myelodysplastic syndrome and acute myeloid leukemia among breast cancer survivors
Henry G. Kaplan, Judith A. Malmgren, Christopher I. Li, Gregory S. Calip
Risk of GWAS-identified genetic variants for breast cancer in a Chinese population: a multiple interaction analysis
Wei Chen, Haiping Song, Rong Zhong, Beibei Zhu, Hui Guo, Jiao Lou, Na Shen, Jiaoyuan Li, Xueqin Chen, Cheng Liu, Jie Ming, Tao Huang, Xiaoping Miao
Cardiovascular disease among breast cancer survivors: the call for a clinical vascular health toolbox
Lynnette M. Jones, Lee Stoner, Casey Brown, Chris Baldi, Blair McLaren
Addition of bevacizumab to three docetaxel regimens as adjuvant therapy for early stage breast cancer
Denise A. Yardley, Lowell Hart, David Waterhouse, Robert Whorf, D. Randolph Drosick, Patrick Murphy, Suprith Badarinath, Brooke R. Daniel, Barrett H. Childs, Howard Burris
Assessing racial/ethnic disparities in chemotherapy treatment among breast cancer patients in context of changing treatment guidelines
Abigail Silva, Garth H. Rauscher, Kent Hoskins, Ruta Rao, Carol Estwing Ferrans